Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC0245 + Irinotecan in ES-SCLC
NCT05731518Phase 2Recruiting
- Sponsor
- BioCity Biopharma
- Start
- Feb 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SC0245 in small cell lung cancer (SCLC) and solid tumor, sponsored by BioCity Biopharma. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 2 more. Started Feb 2023; status: recruiting.
02
Drugs
SC0245
03
Conditions
small cell lung cancer (SCLC)solid tumor
Beyond the preview
Go deeper on NCT05731518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731518.